Genmab A/S (GMAB.CO)

DKK 1486.5

(4.13%)

Long Term Debt Summary of Genmab A/S

  • Genmab A/S's latest annual long term debt in 2023 was 680 Million DKK , up 30.02% from previous year.
  • Genmab A/S's latest quarterly long term debt in 2024 Q2 was 925 Million DKK , down 0.0% from previous quarter.
  • Genmab A/S reported annual long term debt of 523 Million DKK in 2022, up 44.08% from previous year.
  • Genmab A/S reported annual long term debt of 363 Million DKK in 2021, up 31.05% from previous year.
  • Genmab A/S reported quarterly long term debt of 925 Million DKK for 2024 Q2, down 0.0% from previous quarter.
  • Genmab A/S reported quarterly long term debt of 740 Million DKK for 2023 Q1, up 41.49% from previous quarter.

Annual Long Term Debt Chart of Genmab A/S (2023 - 2002)

Historical Annual Long Term Debt of Genmab A/S (2023 - 2002)

Year Long Term Debt Long Term Debt Growth
2023 680 Million DKK 30.02%
2022 523 Million DKK 44.08%
2021 363 Million DKK 31.05%
2020 277 Million DKK 78.71%
2019 155 Million DKK 0.0%
2018 - DKK 0.0%
2017 - DKK 0.0%
2016 - DKK 0.0%
2015 - DKK -100.0%
2014 118 Thousand DKK -66.85%
2013 356 Thousand DKK -81.18%
2012 1.89 Million DKK -68.76%
2011 6.05 Million DKK -48.88%
2010 11.84 Million DKK -33.96%
2009 17.93 Million DKK 100.11%
2008 8.96 Million DKK 9.56%
2007 8.18 Million DKK -27.28%
2006 11.25 Million DKK -22.33%
2005 14.48 Million DKK -30.89%
2004 20.96 Million DKK 12.88%
2003 18.56 Million DKK 74.76%
2002 10.62 Million DKK 0.0%

Peer Long Term Debt Comparison of Genmab A/S

Name Long Term Debt Long Term Debt Difference
ALK-Abelló A/S 439 Million DKK -54.897%
Bavarian Nordic A/S 15.13 Million DKK -4392.897%
Gubra A/S 60.68 Million DKK -1020.54%
Novo Nordisk A/S 20.52 Billion DKK 96.687%
Orphazyme A/S - DKK -Infinity%
Pharma Equity Group A/S 8.07 Million DKK -8324.182%
Zealand Pharma A/S 102.57 Million DKK -562.93%